Report cover image

Minimal Residual Disease Testing Market by Technology (Flow Cyclometry, Next-Generation Sequencing, Polymerase Chain Reaction), Indication (Leukemia, Lymphoma, Myeloma), End-User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 189 Pages
SKU # IRE18446134

Description

Minimal Residual Disease Testing Market by Technology (Flow Cyclometry, Next-Generation Sequencing, Polymerase Chain Reaction), Indication (Leukemia, Lymphoma, Myeloma), End-User - Global Forecast 2024-2030


The Minimal Residual Disease Testing Market size was estimated at USD 1.83 billion in 2023 and expected to reach USD 2.05 billion in 2024, at a CAGR 12.36% to reach USD 4.14 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Minimal Residual Disease Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Minimal Residual Disease Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Minimal Residual Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilus Diagnostics Ltd., Amgen Inc., ARUP Laboratories, AstraZeneca PLC, Asuragen Inc. by Bio-Techne Corporation, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, C2I Genomics Inc., Cergentis B.V., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Genetron Holdings Limited, GRAIL, LLC by Illumina, Inc., Guardant Health, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., Kite Pharma, Inc. by Gilead Sciences, Inc., Laboratory Corporation of America Holdings, Mdxhealth BV, MedGenome Inc, Mission Bio, Inc., Myriad Genetics, Inc., Natera Inc., NeoGenomics Laboratories, Inc., OPKO Health, Inc., Quest Diagnostics incorporated, Sysmex Corporation, and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Minimal Residual Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology

Flow Cyclometry

Next-Generation Sequencing

Polymerase Chain Reaction
Indication

Leukemia

Lymphoma

Myeloma
End-User

Academic & Research Institutes

Diagnostic Laboratories

Hospitals
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Minimal Residual Disease Testing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Minimal Residual Disease Testing Market?
3. What are the technology trends and regulatory frameworks in the Minimal Residual Disease Testing Market?
4. What is the market share of the leading vendors in the Minimal Residual Disease Testing Market?
5. Which modes and strategic moves are suitable for entering the Minimal Residual Disease Testing Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

189 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Minimal Residual Disease Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Need for refine treatment decisions for a variety of cancers
5.1.1.2. Rising prevalence of hematologic malignancies among world population
5.1.2. Restraints
5.1.2.1. High cost associated with the MRD testing
5.1.3. Opportunities
5.1.3.1. Evolution of personalized MRD testing techniques
5.1.3.2. Ongoing development of new minimal residual disease testing methods
5.1.4. Challenges
5.1.4.1. Stringent government regulations for the commercialization of MRD
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Minimal Residual Disease Testing Market, by Technology
6.1. Introduction
6.2. Flow Cyclometry
6.3. Next-Generation Sequencing
6.4. Polymerase Chain Reaction
7. Minimal Residual Disease Testing Market, by Indication
7.1. Introduction
7.2. Leukemia
7.3. Lymphoma
7.4. Myeloma
8. Minimal Residual Disease Testing Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Diagnostic Laboratories
8.4. Hospitals
9. Americas Minimal Residual Disease Testing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Minimal Residual Disease Testing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Minimal Residual Disease Testing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Adaptive Biotechnologies Corporation
13.1.2. Agilus Diagnostics Ltd.
13.1.3. Amgen Inc.
13.1.4. ARUP Laboratories
13.1.5. AstraZeneca PLC
13.1.6. Asuragen Inc. by Bio-Techne Corporation
13.1.7. Bio-Rad Laboratories, Inc.
13.1.8. Bristol-Myers Squibb Company
13.1.9. C2I Genomics Inc.
13.1.10. Cergentis B.V.
13.1.11. Exact Sciences Corporation
13.1.12. F. Hoffmann-La Roche Ltd.
13.1.13. Genetron Holdings Limited
13.1.14. GRAIL, LLC by Illumina, Inc.
13.1.15. Guardant Health, Inc.
13.1.16. Integrated DNA Technologies, Inc.
13.1.17. Invivoscribe, Inc.
13.1.18. Kite Pharma, Inc. by Gilead Sciences, Inc.
13.1.19. Laboratory Corporation of America Holdings
13.1.20. Mdxhealth BV
13.1.21. MedGenome Inc
13.1.22. Mission Bio, Inc.
13.1.23. Myriad Genetics, Inc.
13.1.24. Natera Inc.
13.1.25. NeoGenomics Laboratories, Inc.
13.1.26. OPKO Health, Inc.
13.1.27. Quest Diagnostics incorporated
13.1.28. Sysmex Corporation
13.1.29. Veracyte, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 2. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MINIMAL RESIDUAL DISEASE TESTING MARKET DYNAMICS
FIGURE 7. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us